After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...

New FDA communication introduces a more flexible, risk‑based chemistry, manufacturing, and controls (CMC) framework for cell and gene therapies, including phased data submission to support earlier ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

Detroit allowed the E.V. pioneer Tesla to become the most valuable auto company in the world. But then the auto industry’s ...

Applied Cells Inc. and Immuneel Therapeutics Private Limited today announced that the companies have entered into a collaboration framework to jointly evaluate application of Applied Cells' MARS(R) ...

SHANGHAI and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced today the ...

Cellares and City of Hope are partnering to evaluate automating CAR T manufacturing for glioblastoma brain cancer therapy.

The U.S. Food and Drug Administration declined to approve Atara Biotherapeutics' cell therapy for a ​rare form of blood ...

Presentation at the 44 th J.P. Morgan Healthcare Conference ...

The clearance allows for the clinical manufacturing and release of rese-cel using Cellares’ fully automated end-to-end manufacturing and high-throughput quality control platforms, with first patient ...

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...